PAES: post-authorisation efficacy study
A post-authorisation efficacy study (PAES) is a study an authority can require after approval to resolve remaining doubts about a medicine's efficacy.
Also known as: post-authorization efficacy study
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Articles 21a(f) and 22a(1)(b) of Directive 2001/83/EC; Articles 9(4)(cc) and 10a(1)(b) of Regulation (EC) No 726/2004
- When it can be required
- The situations listed in Delegated Regulation (EU) No 357/2014
- Imposed by
- National competent authorities, EMA or the Commission
- Recorded in
- The conditions of the marketing authorisation and the risk management plan
How it works
A post-authorisation efficacy study addresses a scientific uncertainty about the efficacy of an authorised medicine, within its authorised indication, that an authority has identified. The 2010 pharmacovigilance legislation gave authorities the power to impose one. Under Article 21a(f) of Directive 2001/83/EC and Article 9(4)(cc) of Regulation (EC) No 726/2004, a study can be made a condition when the authorisation is granted, where concerns about some aspect of efficacy can be resolved only after the product has been marketed. Under Article 22a(1)(b) of the Directive and Article 10a(1)(b) of the Regulation it can be imposed later, where the understanding of the disease or the clinical methodology indicates that earlier efficacy evaluations might have to be revised significantly.
Commission Delegated Regulation (EU) No 357/2014 limits when the power can be used. A study may be required only where one or more listed cases arise: an initial assessment based on surrogate endpoints that needs verifying against clinical outcome or disease progression; a medicine used in combination with others, where further efficacy data are needed; uncertainty about efficacy in certain sub-populations; a potential lack of efficacy in the long term; benefits shown in clinical trials that are significantly affected by use under real-life conditions; a change in the understanding of the standard of care or of the pharmacology of the medicine; and new concrete and objective scientific factors suggesting that earlier evaluations might need significant revision. Efficacy studies required as specific obligations of a conditional marketing authorisation rest on their own legal basis.
An imposed study appears as a condition of the marketing authorisation, in section D of Annex II for centrally authorised products, and in Part IV of the risk management plan, with a due date for the final results. When the obligation is imposed after authorisation, the authority notifies the holder in writing, with its reasons and the timeframe, and the holder can ask within 30 days to submit written observations before the obligation is withdrawn or confirmed. A confirmed obligation is added to the authorisation as a condition. Article 108a of the Directive requires EMA to draw up scientific guidance on these studies, which covers the choice of design and the place of randomised and observational studies. Results are submitted for assessment and, where they change the conclusions on efficacy, lead to a variation of the product information.
A PAES is not a PASS. A safety study investigates risk and has its own procedural chapter in Articles 107m to 107q of the Directive. An efficacy study tests benefit and has no equivalent chapter, so the conditions of the authorisation and the scientific guidance govern how it is run. One study can pursue both aims, in which case both sets of expectations apply. Efficacy studies that a holder runs on its own initiative are outside this framework.
What goes wrong
A design that cannot answer the question the authority asked, usually because the comparator or endpoint was chosen for convenience; dates in the authorisation that slip without a variation to change them; recruitment that fails once the product is reimbursed and the standard of care has moved on; results described in a PSUR but never submitted for assessment as the condition requires; and treating the obligation as closed when the final report is filed, before the authority has agreed that the condition is fulfilled. An unmet condition can lead to regulatory action on the authorisation itself.
Timing
Notification
The authority informs the holder in writing of the obligation, its objectives and the timeframe.
Within 30 days
The holder may ask to submit written observations on the obligation.
Confirmation
The authority withdraws or confirms the obligation; if confirmed, it becomes a condition of the authorisation and the risk management plan is updated.
Due date in the condition
Final study results submitted for assessment.
There is no fixed statutory timetable for the study. The condition in the marketing authorisation sets the due date for the final results, and changing it needs a variation. Where the obligation is imposed after authorisation, the holder has 30 days from receipt of the written notification to ask to submit observations, within a time limit the authority then sets.
PAES: common questions
What is the difference between a PAES and a PASS?
A PAES resolves uncertainty about how well a medicine works; a PASS investigates a safety risk or the effectiveness of risk minimisation. Both can be imposed as conditions of the marketing authorisation, but only non-interventional imposed safety studies follow the protocol endorsement procedure in Articles 107n to 107q of Directive 2001/83/EC. Efficacy studies are governed by the condition itself, Delegated Regulation (EU) No 357/2014 and EMA's scientific guidance.
When can an authority require a PAES?
Only in the situations listed in Delegated Regulation (EU) No 357/2014, for example where approval rested on surrogate endpoints, where efficacy in a sub-population or in the long term is uncertain, or where real-life use significantly affects the benefit shown in trials. The obligation can be set when the authorisation is granted or afterwards, and the authority must give its reasons in writing.
Can a holder object to a PAES imposed after authorisation?
Yes. Under Article 22a of Directive 2001/83/EC the holder can ask, within 30 days of receiving the written notification, to present written observations within a time limit set by the authority. On the basis of those observations the authority withdraws or confirms the obligation. If it is confirmed, the marketing authorisation is varied to include it as a condition.
Sources
- EUR-Lex: Commission Delegated Regulation (EU) No 357/2014 on situations in which post-authorisation efficacy studies may be required
- EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use (Articles 21a, 22a and 108a)
- European Medicines Agency: Post-authorisation efficacy studies: questions and answers